Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tumor progression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4,616 result(s) found for: Tumor progression. Displaying page 1 of 231.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-003936-21 Sponsor Protocol Number: TD-212-2308 Start Date*: 2015-09-14
    Sponsor Name:Hôpital de Jolimont
    Full Title: A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THE...
    Medical condition: Progressive well or moderately differentiated neuroendocrine tumour of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002512-14 Sponsor Protocol Number: AK2017-2 Start Date*: 2017-09-04
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-002312-13 Sponsor Protocol Number: AK2017-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet
    Full Title: PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105
    Medical condition: Patients with neuroendocrine tumors (gastro-entero-pancreatic and bronchopulmonary)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10078184 Neuroendocrine tumor of the lung metastatic LLT
    20.0 100000004864 10078183 Neuroendocrine tumor of the lung LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    20.0 100000004864 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    20.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006964-48 Sponsor Protocol Number: 20040215 Start Date*: 2007-04-13
    Sponsor Name:Amgen Inc
    Full Title: An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone
    Medical condition: Giant Cell Tumor (GCT) of bone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005968 Bone giant cell tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001725-24 Sponsor Protocol Number: CTKI258AIC02 Start Date*: 2011-10-03
    Sponsor Name:Novartis Pharma Services
    Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib
    Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004069-14 Sponsor Protocol Number: PRODIGE31 Start Date*: 2015-01-22
    Sponsor Name:Fédération Francophone de Cancérologie Digestive (FFCD)
    Full Title: A european, multicentre, phase II/III randomised double-blind, placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrin...
    Medical condition: Non-resectable duodeno-pancreatic neuroendocrine tumours after first line treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006097-76 Sponsor Protocol Number: LOTUS Start Date*: 2013-01-11
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDO...
    Medical condition: PATIENTS WITH NEUROENDOCRINE TUMOR AND INOPERABLE LIVER METASTASIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002540-67 Sponsor Protocol Number: 2019-06 Start Date*: 2022-04-08
    Sponsor Name:Centre Oscar Lambret
    Full Title: Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumor
    Medical condition: Wilms tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029145 Nephroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003666-41 Sponsor Protocol Number: IJBMNLUMEN Start Date*: 2013-05-27
    Sponsor Name:Jules Bordet Institute
    Full Title: The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours
    Medical condition: Patients with proved progressive (or refractory to standard systemic therapy available in Belgium at the time of inclusion) neuroendocrine tumors, not amenable to surgical resection with curative i...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001467-39 Sponsor Protocol Number: GETNE1509 Start Date*: 2015-07-24
    Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos)
    Full Title: A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.
    Medical condition: Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohor...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003612-45 Sponsor Protocol Number: A9001502 Start Date*: 2019-09-06
    Sponsor Name:Pfizer Inc.
    Full Title: TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005919-30 Sponsor Protocol Number: AK_NEN_DOTA-FDG_21 Start Date*: 2022-09-21
    Sponsor Name:Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet
    Full Title: Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms
    Medical condition: Neuroendocrine neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077560 Gastroenteropancreatic neuroendocrine tumor disease LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067518 Pancreatic neuroendocrine tumor LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085846 Duodenal neuroendocrine tumor LLT
    24.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10085958 Small intestine neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000741-46 Sponsor Protocol Number: 2017/2523 Start Date*: 2017-10-06
    Sponsor Name:Gustave Roussy
    Full Title: RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
    Medical condition: Pancreatic well differentiated neuroendocrine tumors (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000283-28 Sponsor Protocol Number: IB_2013–01 Start Date*: 2013-11-13
    Sponsor Name:Institut Bergonié
    Full Title: Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study
    Medical condition: Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002142-37 Sponsor Protocol Number: SURGE 01-07 Start Date*: 2007-08-03
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: SUNITINIB (SUTENT, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiforme An Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies
    Medical condition: Glioblastoma multiforme - WHO grade IV First progression/recurrence
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000726-66 Sponsor Protocol Number: GETNE1206 Start Date*: 2014-10-08
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by ...
    Medical condition: advanced progressive pNETs
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) IT (Completed) ES (Completed) DK (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-002980-81 Sponsor Protocol Number: CO-3810-101 Start Date*: 2021-02-10
    Sponsor Name:Clovis Oncology, Inc.
    Full Title: LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor
    Medical condition: Advanced gynecological solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002192-18 Sponsor Protocol Number: TRIO020 Start Date*: 2013-10-17
    Sponsor Name:Translational Research In Oncology
    Full Title: A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression
    Medical condition: Advanced ER+, HER2- postmenopausal breast cancer with low ER expression
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-000357-35 Sponsor Protocol Number: CAMN107DDE05 Start Date*: 2008-11-04
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib
    Medical condition: metastatic or unresectable gastrointestinal stromal tumor in patients resistant to imatinib or sunitinib
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017957-37 Sponsor Protocol Number: BAY73-4506/14874 Start Date*: 2010-12-14
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gas...
    Medical condition: Metastatic and /or unresectable gastrointestinal tumors (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) NL (Completed) DE (Completed) GB (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:23:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA